Latest oropharyngeal candidiasis Stories

2011-05-11 01:00:00

TOKYO, May 11, 2011 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announces that Sosei Co., Ltd., its wholly owned Japanese subsidiary, acquired development and commercialization rights to Loramyc(R) (miconazole Lauriad(R). Sosei development code: SO-1105) in Japan from BioAlliance Pharma. Loramyc(R) is an antifungal agent, administered as a muco-adhesive buccal tablet for the treatment of oropharyngeal...

2010-04-16 12:17:00

WOODCLIFF LAKE, N.J., April 16 /PRNewswire/ -- Strativa Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved Oravig (miconazole) buccal tablets for the treatment of oropharyngeal candidiasis (OPC), more commonly known as thrush, in adults and children age 16 and older. Oravig is the first and only local, oral prescription formulation of miconazole - an antifungal medication - approved for this use in the U.S. Oravig, which adheres to the gum,...

2008-07-21 12:01:26

BioAlliance Pharma SA (Euronext Paris ISIN code: FR0010095596-BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, has published a turnover of EUR 1,749,000 for the second quarter of 2008, compared with EUR 199,000 recorded for the same period in 2007. The company also presented the initial trends for Loramyc(R) sales in France and its plan for marketing in Europe. BioAlliance Pharma will host two conference calls tomorrow...

Word of the Day
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.